Systematic overview of warfarin and its drug and food interactions

Archives of Internal Medicine

Volumn 165, Issue 10, 2005, Pages 1095-1106

  Holbrook, Anne M ^a,b,c   Pereira, Jennifer A ^a,b,c   Labiris, Renee ^a   McDonald, Heather ^d   Douketis, James D ^b   Crowther, Mark ^b   Wells, Philip S ^e  

^a CENTRE FOR EVALUATION OF MEDICINES   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d Axon Clinical Research   (Canada)

^e UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ACETYLSALICYLIC ACID; ALCOHOL; ALPHA TOCOPHEROL; AMIODARONE; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANABOLIC AGENT; ANASTROZOLE; ANTACID AGENT; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; ARGATROBAN; ATENOLOL; ATORVASTATIN; AZATHIOPRINE; AZITHROMYCIN; BARBITURIC ACID DERIVATIVE; BEZAFIBRATE; BOSENTAN; BUMETADINE; CANDESARTAN HEXETIL; CARBAMAZEPINE; CARBOPLATIN; CEFAMANDOLE; CEFAZOLIN; CELECOXIB; CEPHALOSPORIN; CHELATING AGENT; CHLORAL HYDRATE; CHLORAMPHENICOL; CHLORDIAZEPOXIDE; CILOMILAST; CILOSTAZOL; CIMETIDINE; CIPROFLOXACIN; CITALOPRAM; CLARITHROMYCIN; CLOFIBRATE; CLOPIDOGREL; CLOXACILLIN; COLESTYRAMINE; COTRIMOXAZOLE; CURBICIN; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOCHROME P450 1A2; CYTOCHROME P450 3A4; DANAZOL; DEXTROPROPOXYPHENE; DIAZEPAM; DICLOXACILLIN; DIFLUNISAL; DILTIAZEM; DIPYRIDAMOLE; DISOPYRAMIDE; DISULFIRAM; DONEPEZIL; ENOXACIN; ENTACAPONE; EPROSARTAN; ERYTHROMYCIN; ETIRACETAM; ETODOLAC; ETOPOSIDE; ETRETINATE; FAMOTIDINE; FELBAMATE; FELODIPINE; FENOFIBRATE; FENUGREEK EXTRACT; FISH OIL; FLUCONAZOLE; FLUINDOSTATIN; FLUOROURACIL; FLUOXETINE; FLUVOXAMINE; FONDAPARINUX; FUROSEMIDE; GATIFLOXACIN; GEMCITABINE; GEMFIBROZIL; GEMIFLOXACIN; GINSENG EXTRACT; GREEN TEA EXTRACT; GRISEOFULVIN; HEPARIN; HERBACEOUS AGENT; IBUPROFEN; IFOSFAMIDE; INDOMETACIN; INFLUENZA VACCINE; INTERFERON; ISONIAZID; ISPAGULA; ITRACONAZOLE; KETOCONAZOLE; KETOPROFEN; KETOROLAC; LEFLUNOMIDE; LEVAMISOLE; LEVOFLOXACIN; LEVONORGESTREL; LEVOSIMENDAN; LEVOTHYROXINE; LOOP DIURETIC AGENT; LOSARTAN; MACROLIDE; MELOXICAM; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METHYLPREDNISOLONE; METOLAZONE; METOPROLOL; METRIFONATE; METRONIDAZOLE; MEVINOLIN; MICONAZOLE; MIGLITOL; MODAFINIL; MOEXIPRIL; MONTELUKAST; MORACIZINE; MULTIVITAMIN; NABUMETONE; NAFCILLIN; NALIDIXIC ACID; NAPROXEN; NATEGLINIDE; NEFAZODONE; NIZATIDINE; NONSTEROID ANTIINFLAMMATORY AGENT; NORFLOXACIN; OFLOXACIN; OMEPRAZOLE; PACLITAXEL; PANTOPRAZOLE; PARACETAMOL; PC SPES; PENICILLIN G; PHENYLBUTAZONE; PHENYTOIN; PIROXICAM; PLANT EXTRACT; PROPAFENONE; PROPOFOL; PROPRANOLOL; PYRROLE; QUETIAPINE; QUILINGGAO EXTRACT; QUINIDINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RALOXIFENE; RANITIDINE; RIBAVIRIN; RIFAMPICIN; RITONAVIR; ROFECOXIB; ROPINIROLE; SALAZOSULFAPYRIDINE; SALICYLIC ACID; SALICYLIC ACID METHYL ESTER; SALVIA MILTIORRHIZA EXTRACT; SAQUINAVIR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SEVELAMER; SIMVASTATIN; SUCRALFATE; SUCROSE POLYESTER; SULFAFURAZOLE; SULFINPYRAZONE; SULINDAC; TAMOXIFEN; TEICOPLANIN; TELMISARTAN; TERBINAFINE; TETRACYCLINE; TETRAHYDROLIPSTATIN; TICLOPIDINE; TOLMETIN; TOLTERODINE; TRAMADOL; TRANEXAMIC ACID; TRASTUZUMAB; TRAZODONE; TROGLITAZONE; UBIDECARENONE; UNCLASSIFIED DRUG; VANCOMYCIN; VITAMIN K GROUP; VORICONAZOLE; WARFARIN; ZILEUTON;

AVOCADO; BRAIN HEMORRHAGE; CLINICAL TRIAL; CRANBERRY; DRUG ANTAGONISM; DRUG CLEARANCE; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; FENUGREEK; FOOD DRUG INTERACTION; GRAPEFRUIT JUICE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LYCIUM; MANGO; PRIORITY JOURNAL; REVIEW; SEAWEED; SOYBEAN MILK; STEREOCHEMISTRY; SUPPOSITORY; THROMBOSIS; TOBACCO;

ANTICOAGULANTS; CLINICAL TRIALS; FOOD-DRUG INTERACTIONS; HUMANS; WARFARIN;

EID: 19344366484     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.165.10.1095     Document Type: Review

References (248)

1. Albers GW, Dalen JE, Laupacis A, Manning WJ, Petersen P, Singer DE. Antithrombotic therapy in atrial fibrillation. Chest. 2001;119(suppl):194S-206S.
2. Stein PD, Alpert JS, Bussey HI, Dalen JE, Turpie AGG. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves [published correction appears in Chest. 2001;120:1044]. Chest. 2001;119(suppl):220S-227S.
3. Hyers TMAG, Hull RD, Morris TA, Samama M, Tapson V, Weg JG. Antithrombotic therapy for venous thromboembolic disease. Chest. 2001;119(suppl):176S-193S.
4. Cairns JA, Theroux P, Lewis HD Jr, Ezekowitz M, Meade TW. Antithrombotic agents in coronary artery disease [published correction appears in Chest 2001;120:1427]. Cnest. 2001;119(suppl):228S-252S.
5. Hirsh J, Dalen J, Anderson DR, et al. Oral anticoagulants: mechanism of action clinical effectiveness and optimal therapeutic range. Chest. 2001;119(suppl 1):8S-21S.
6. Wells PS, Holbrook AM, Crowther NR, Hirsh J. Interactions of warfarin with drugs and food. Ann Intern Med. 1994;121:676-683.
7. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med. 1998;105:91-99.
8. Fleiss JL. Statistical Methods for Rates and Proportions. New York, NY: John Wiley & Sons; 1981:212-225.
9. Stading JA, Skrabal MZ, Faulkner MA. Seven cases of interaction between warfarin and cyclooxygenase-2 inhibitors. Am J Health Syst Pharm. 2001;58:2076-2080.
10. Mersfelder TL, Stewart LR. Warfarin and celecoxib interaction. Ann Pharmacother. 2000;34:325-327.
11. Wood GD, Deeble T. Warfarin: dangers with antibiotics. Dent Update. 1993;20:350-353.
12. Beckey MP, Korman LB, Parra D. Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy. Pharmacotherapy. 1999;19:1075-1079.
13. Kim JM, White RH. Effect of vitamin E on the anticoagulant response to warfarin. Am J Cardiol. 1996;77:545-546.
14. Lidell C, Svedberg LE, Lindell P, Bandh S, Job B, Wallentin L. Clopidogrel and warfarin: absence of interaction in patients receiving long-term anticoagulant therapy for non-valvular atrial fibrillation. Thromb Haemost. 2003;89:842-846.
15. Engelsen J, Nielsen JD, Hansen KE. Effect of coenzyme Q10 and ginkgo biloba on warfarin dosage in patients on long-term warfarin treatment: a randomized double-blind, placebo-controlled cross-over trial. Ugeskr Laeger. 2003;165:1868-1871.
16. Israel DS, Stotka J, Rock W, et al. Effect of ciprofloxacin on the pharmacokinetics and pharmacodynamics of warfarin. Clin Infect Dis. 1996;22:251-256.
17. Gebauer MG, Nyfort-Handsen K, Henschke PJ, Gallus AS. Warfarin and acetaminophen interaction. Pharmacotherapy. 2003;23:109-112.
18. Lambert J, Cormier J. Potential interaction between warfarin and boldo-fenugreek. Pharmacotherapy. 2001;21:509-512.
19. Priskorn M, Sidhu JS, Larsen F, Davis JD, Khan AZ, Rolan PE. Investigation of multiple dose citalopram on the pharmacokinetics and pharmacodynamics of racemic warfarin. Br J Clin Pharmacol. 1997;44:199-202.
20. Stoysich AM, Lucas BD, Mohiuddin SM, Hilleman DE. Further elucidation of pharmacokinetic interaction between diltiazem and warfarin. Int J Clin Pharmacol Ther. 1996;34:56-60.
21. Dingemanse J, Meyerhoff C, Schadrack J. Effect of the catechol-O-methyltransferase inhibitor entacapone on the steady-state pharmacokinetics and pharmacodynamics of warfarin. Br J Clin Pharmacol. 2002;53:485-491.
22. Ascah KJ, Rock GA, Wells PS. Interaction between fenofibrate and warfarin. Ann Pharmacother. 1998;32:765-768.
23. Buckley MS, Goff AD, Knapp WE. Fish oil interaction with warfarin. Ann Pharmacother. 2004;38:50-53.
24. Monterrey-Rodriguez J. Interaction between warfarin and mango fruit [letter]. Ann Pharmacother. 2002;36:940-941.
25. Thirion DJ, Zanetti LA. Potentiation of warfarin's hypoprothrombinemic effect with miconazole vaginal suppositories. Pharmacotherapy. 2000;20:98-99.
26. Wong ALN, Chan TYK. Interaction between warfarin and the herbal product quilinggao. Ann Pharmacother. 2003;37:836-838.
27. Apseloff G, Wilner KD, Gerber N, Tremaine LM. Effect of sertraline on protein binding of warfarin. Clin Pharmacokinet. 1997;32(suppl 1):37-42.
28. Purkins L, Wood N, Kleinermans D, Nichols D. Voriconazole potentiates warfarin-induced prothrombin time prolongation. Br J Clin Pharmacol. 2003;56:24-29.
29. Awni WM, Hussein Z, Granneman GR, Patterson KJ, Dube LM, Cavanaugh JH. Pharmacodynamic and stereoselective pharmacokinetic interactions between zileuton and warfarin in humans. Clin Pharmacokinet. 1995;29(suppl 2):67-76.
30. Ermer JC, Hicks DR, Wheeler SC, Kraml M, Jusko WJ. Concomitant etodolac affects neither the unbound clearance nor the pharmacologic effect of warfarin. Clin Pharmacol Ther. 1994;55;305-316.
31. Martin LA, Mehta SD. Diminished anticoagulant effects of warfarin with concomitant mercaptopurine therapy. Pharmacotherapy. 2003;23:260-264.
32. Marinella MA. Mesalamine and warfarin therapy resulting in decreased warfarin effect. Ann Pharmacother. 1998;32:841-842.
33. Schulman S. Inhibition of warfarin activity by ribavirin. Ann Pharmacother. 2002;36:72-74.
34. Small NL, Giamonna KA. Interaction between warfarin and trazodone. Ann Pharmacother. 2000;34:734-736.
35. Yates RA, Wong J, Seiberling M, Merz M, Marz W, Nauck M. The effect of anastrozole on the single-dose pharmacokinetics and anticoagulant activity of warfarin in healthy volunteers. Br J Clin Pharmacol. 2001;51:429-435.
36. Brown PM, Hursting MJ. Lack of pharmacokinetic interactions between argatroban and warfarin. Am J Health Syst Pharm. 2002;59:2078-2083.
37. Mallikaarjun S, Bramer SL. Effect of cilostazol on the pharmacokinetics and pharmacodynamics of warfarin. Clin Pharmacokinet. 1999;37 (suppl 2):79-86.
38. Tiseo PJ, Foley K, Friedhoff LT. The effect of multiple doses of donepezil HCI on the pharmacokinetic and pharmacodynamic profile of warfarin. Br J Clin Pharmacol. 1998;46(suppl 1):45-50.
39. Kazierad DJ, Martin DE, Ilson B, et al. Eprosartan does not affect the pharmacodynamics of warfarin. J Clin Pharmacol. 1998;38:649-653.
40. Faaij RA, Burggraaf J, Schoemaker RC, van Amsterdam RGM, Cohen AF. Absence of an interaction between the synthetic pentasaccharide fondaparinux and oral warfarin. Br J Clin Pharmacol. 2002;54:304-308.
41. Davy M, Bird N, Rost KL, Fuder H. Lack of effect of gemifloxacin on the steady-state pharmacodynamics of warfarin in healthy volunteers. Chemotherapy. 1999;45:491-495.
42. Ragueneau-Majlessi I, Levy RH, Meyerhoff C. Lack of effect of repeated administration of levetiracetam on the pharmacodynamic and pharmacokinetic profiles of warfarin. Epilepsy Res. 2001;47:55-63.
43. Kong AN, Tomasko L, Waldman SA, et al. Losartan does not affect the pharmacokinetics and pharmacodynamics of warfarin. J Clin Pharmacol. 1995;35:1008-1015.
44. Turck D, Su CA, Heinzel G, Busch U, Bluhmki E, Hoffmann J. Lack of interaction between meloxicam and warfarin in healthy volunteers. Eur J Clin Pharmacol. 1997;51:421-425.
45. Heinig R, Kitchin N, Rolan P. Disposition of a single dose of warfarin in healthy individuals after pretreatment with metrifonate. Clin Drug Invest. 1999;18:151-159.
46. Schall R, Muller FO, Hundt HK, Duursema L, Groenewoud G, Middle MV. Study of the effect of miglitol on the pharmacokinetics and pharmacodynamics of warfarin in healthy males. Arzneimittelforschung. 1996;46:41-46.
47. Robertson P Jr, Hellriegel ET, Arora S, Nelson M. Effect of modafinil at steady state on the single-dose pharmacokinetic profile of warfarin in healthy volunteers. J Clin Pharmacol. 2002;42:205-214.
48. Van Hecken A, Verbesselt R, Depre M, et al. Moexipril does not alter the pharmacokinetics or pharmacodynamics of warfarin. Eur J Clin Pharmacol. 1993;45:291-293.
49. Van Hecken A, Depre M, Verbesselt R, et al. Effect of montelukast on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. J Clin Pharmacol. 1999;39:495-500.
50. Anderson DM, Shelley S, Crick N, Buraglio M. No effect of the novel antidiabetic agent nateglinide on the pharmacokinetics and anticoagulant properties of warfarin in healthy volunteers. J Clin Pharmacol. 2002;42:1358-1365.
51. Salazar DE, Dockens RC, Milbrath RL, et al. Pharmacokinetic and pharmacodynamic evaluation of warfarin and nefazodone coadministration in healthy subjects. J Clin Pharmacol. 1995;35:730-738.
52. Duursema L, Muller FO, Schall R, et al. Lack of effect of pantoprazole on the pharmacodynamics and pharmacokinetics of warfarin. Br J Clin Pharmacol. 1995;39:700-703.
53. Burke S, Amin N, Incerti C, Plone M, Watson N. Sevelamer hydrochloride a nonabsorbed phosphate-binding polymer does not interfere with digoxin or warfarin pharmacokinetics. J Clin Pharmacol. 2001;41:193-198.
54. Byrd DC, Gaskins SE, Parrish AM, Freeman LB. Warfarin and ciprofloxacin interaction: case report and controversy. J Am Board Fam Pract. 1999;12:486-488.
55. McMorran M, Morawiecka I. Celecoxib (Celebrex): 1 year later. CMAJ. 2000;162:1044-1046, 1048-1050.
56. Dent LA, Orrock MW. Warfarin-fluoxetine and diazepam-fluoxetine interaction. Pharmacotherapy. 1997;17:170-172.
57. Guerret M, Francheteau P, Huber M. Evaluation of effects of terbinafine on single oral dose pharmacokinetics and anticoagulant actions of warfarin in healthy volunteers. Pharmacotherapy. 1997;17:767-773.
58. Warwick JA, Corrall RJ. Serious interaction between warfarin and oral terbinafine. BMJ. 1998;316:440.
59. Gupta AK, Ross GS. Interaction between terbinafine and warfarin. Dermatology. 1998;196:266-267.
60. Newshan G, Tsang P. Ritonavir and warfarin interaction. AIDS. 1999;13:1788-1789.
61. Poli D, Chiarugi L, Capanni IW, et al. Need of more frequent international normalized ratio monitoring in elderly patients on long-term anticoagulant therapy after influenza vaccination. Blood Coagul Fibrinolysis. 2002;13:297-300.
62. Lipsky BA, Pecoraro RE, Roben NJ, de Blaquiere P, Delaney CJ. Influenza vaccination and warfarin anticoagulation. Ann Intern Med. 1984;100:835-837.
63. Kramer P, Tsuru M, Cook CE, McClain CJ, Holtzman JL. Effect of influenza vaccine on warfarin anticoagulation. Clin Pharmacol Ther. 1984;35:416-418.
64. Duursema L, Muller FO, Hundt HK, Heyns AO, Meyer BH, Luus HG. Model to detect warfarin-drug interactions in man. Drug Investig. 1992;4:395-402.
65. Heimark LD, Wienkers L, Kunze K, et al. The mechanism of the interaction between amiodarone and warfarin in humans. Clin Pharmacol Ther. 1992;51:398-407.
66. Almog S, Shafran N, Halkin H, et al. Mechanism of warfarin potentiation by amiodarone: dose and concentration-dependent inhibition of warfarin elimination. Eur J Clin Pharmacol. 1985;28:257-261.
67. O'Reilly RA, Trager WF, Rettie AE, Goulart DA. Interaction of amiodarone with racemic warfarin and its separated enantiomorphs in humans. Clin Pharmacol Ther. 1987;42:290-294.
68. Pyorala K, Myllyla G, Kekki M. Metabolism of warfarin during methandrostenolone treatment. Ann Med Exp Biol Fenn. 1965;43:95-97.
69. Lorentz SM, Weibert RT. Potentiation of warfarin anticoagulation by topical testosterone ointment. Clin Pharm. 1985;4:332-334.
70. Toon S, Hopkins KJ, Garstang FM, Rowland M. Comparative effects of ranitidine and cimetidine on the pharmacokinetics and pharmacodynamics of warfarin in man. Eur J Clin Pharmacol. 1987;32:165-172.
71. O'Reilly RA. Comparative interaction of cimetidine and ranitidine with racemic warfarin in man. Arch Intern Med. 1984;144:989-991.
72. Bell WR, Anderson KC, Noe DA, Silver BA. Reduction in the plasma clearance rate of warfarin induced by cimetidine. Arch Intern Med. 1986;146:2325-2328.
73. Serlin MJ, Sibeon RG, Mossman S, et al. Cimetidine: interaction with oral anticoagulants in man. Lancet. 1979;2:317-319.
74. Sax MJ, Randolph WC, Peace KE, et al. Effect of two cimetidine regimens on prothrombin time and warfarin pharmacokinetics during long-term warfarin therapy [published correction appears in Clin Pharm. 1988;7:269]. Clin Pharm. 1987;6:492-495.
75. Hunt BA, Sax MJ, Chretien S, Frank WO, Braverman AJ. Stereoselective alterations in the pharmacokinetics of warfarin enantiomers with two cimetidine dose regimens. Pharmacotherapy. 1989;9:184.
76. O'Reilly RA, Sahud MA, Robinson AJ. Studies on the interaction of warfarin and clofibrate in man. Thromb Diath Haemorrh. 1972;27:309-318.
77. O'Reilly RA, Motley CH. Racemic warfarin and trimethoprim- sulfamethoxazole interaction in humans. Ann Intern Med. 1979;91:34-36.
78. Weibert RT, Lorentz SM, Townsend RJ, Cook CE, Klauber MR, Jagger PI. Effect of erythromycin in patients receiving long-term warfarin therapy. Clin Pharm. 1989;8:210-214.
79. Black D, Evans J, Seaton T, Gidal B, McDonnell N, Kunze K. Evaluation of the effect of fluconazole on the stereoselective metabolism of warfarin [abstract]. Clin Pharmacol Ther. 1992;51:piii-52.
80. Rosenthal AB, Self TH, Baker ED, Linden RA. Interaction of isoniazid and warfarin. JAMA. 1977;238:2177.
81. O'Reilly RA. The stereoselective interaction of warfarin and metronidazole in man. N Engl J Med. 1976;295:354-357.
82. O'Reilly RA, Goulart DA, Kunze KL, et al. Mechanisms of the stereoselective interaction between miconazole and racemic warfarin in human subjects. Clin Pharmacol Ther. 1992;51:656-667.
83. Sutfin T, Balmer K, Bostrom H, Eriksson S, Hoglund P, Paulsen O. Stereoselective interaction of omeprazole with warfarin in healthy men. Ther Drug Monit. 1989;11:176-184.
84. Aggeler PM, O'Reilly RA, Leong L, Kowitz PE. Potentiation of anticoagulant effect of warfarin by phenylbutazone. N Engl J Med. 1967;276:496-501.
85. O'Reilly RA, Trager WF, Motley CH, Howald W. Stereoselective interaction of phenylbutazone with [12C/13C] warfarin pseudoracemates in man. J Clin Invest. 1980;65:746-753.
86. Rhodes RS, Rhodes PJ, Klein C, Sintek CD. A warfarin-piroxicam drug interaction. Drug Intell Clin Pharm. 1985;19:556-558.
87. Kates RE, Yee YG, Kirsten EB. Interaction between warfarin and propafenone in healthy volunteer subjects. Clin Pharmacol Ther. 1987;42:305-311.
88. Scott AK, Park BK, Breckenridge AM. Interaction between warfarin and propranolol. Br J Clin Pharmacol. 1984;17(suppl 1):86S.
89. Bax ND, Lennard MS, Tucker GT, et al. The effect of beta-adrenoceptor antagonists on the pharmacokinetics and pharmacodynamics of warfarin. Br J Clin Pharmacol. 1984;17(suppl 1):85S.
90. Nenci GG, Agnelli G, Berrettini M. Biphasic sulphinpyrazone-warfarin interaction. Br Med J (Clin Res Ed). 1981;282:1361-1362.
91. O'Reilly RA. Stereoselective interaction of sulfinpyrazone with racemic warfarin and its separated enantiomorphs in man. Circulation. 1982;65:202-207.
92. Toon S, Low LK, Gibaldi M, et al. The warfarin-sulfinpyrazone interaction: stereochemical considerations. Clin Pharmacol Ther. 1986;39:15-24.
93. O'Reilly RA, Trager WF, Motley CH, Howald W. Interaction of secobarbital with warfarin pseudoracemates. Clin Pharmacol Ther. 1980;28:187-195.
94. Orme M, Breckenridge A. Enantiomers of warfarin and phenobarbital. N Engl J Med. 1976;295:1482-1483.
95. Hansen JM, Siersboek-Nielsen K, Skovsted L. Carbamazepine-induced acceleration of diphenylhydantoin and warfarin metabolism in man. Clin Pharmacol Ther. 1971;12:539-543.
96. Breckenridge A, Orme M. Clinical implications of enzyme induction. Ann N Y Acad Sci. 1971;179:421-430.
97. Robinson DS, Benjamin DM, McCormack JJ. Interaction of warfarin and nonsystemic gastrointestinal drugs. Clin Pharmacol Ther. 1971;12:491-495.
98. Jahnchen E, Meinertz T, Gilfrich HJ, Kersting F, Groth U. Enhanced elimination of warfarin during treatment with cholestyramine. Br J Clin Pharmacol. 1978;5:437-440.
99. Okino K, Weibert RT. Warfarin-griseofulvin interaction. Drug Intell Clin Pharm. 1986;20:291-293.
100. Cullen SI, Catalano P. Griseofulvin-warfarin antagonism. JAMA. 1967;199:582-583.
101. Qureshi GD, Reinders TP, Somori GJ, Evans HJ. Warfarin resistance with nafcillin therapy. Ann Intern Med. 1984;100:527-529.
102. O'Reilly RA. Interaction of sodium warfarin and rifampin: studies in man. Ann Intern Med. 1974;81:337-340.
103. Heimark LD, Gibaldi M, Trager WF, O'Reilly RA, Goulart DA. The mechanism of the warfarin-rifampin drug interaction in humans. Clin Pharmacol Ther. 1987;42:388-394.
104. Mungall D, Talbert RL, Phillips C, Jaffe D, Ludden TM. Sucralfate and warfarin [letter]. Ann Intern Med. 1983;98:557.
105. Talbert RL, Dalmady-Israel C, Bussey HI, Crawford MH, Ludden TM. Effect of sucralfate on plasma warfarin concentration in patients requiring chronic warfarin therapy. Drug Intell Clin Pharm. 1985;19:59.
106. Qureshi GD, Reinders TP, Swint JJ, Slate MB. Acquired warfarin resistance and weight-reducing diet. Arch Intern Med. 1981;141:507-509.
107. Parr MD, Record KE, Griffith GL, Zeok JV, Todd EP. Effect of enterai nutrition on warfarin therapy. Clin Pharm. 1982;1:274-276.
108. Blickstein O, Shaklai M, Inbal A. Warfarin antagonism by avocado [letter]. Lancet. 1991;337:914-915.
109. O'Reilly RA. Lack of effect of fortified wine ingested during fasting and anticoagulant therapy. Arch Intern Med. 1981;141:458-459.
110. O'Reilly RA. Lack of effect of mealtime wine on the hypoprothrombinemia of oral anticoagulants. Am J Med Sci. 1979;277:189-194.
111. Nipper H, Kirby S, Iber FL. Effect of bumetanide on the serum disappearance of warfarin sodium. J Clin Pharmacol. 1981;21:654-656.
112. Serlin MJ, Mossman S, Sibeon RG, Tempero KF, Breckenridge AM. Interaction between diflunisal and warfarin. Clin Pharmacol Ther. 1980;28:493-498.
113. Toon S, Hopkins KJ, Garstang FM, Aarons L, Sedman A, Rowland M. Enoxacin-warfarin interaction: pharmacokinetic and stereochemical aspects. Clin Pharmacol Ther. 1987;42:33-41.
114. De Lepeleire I, Van Hecken A, Verbesselt R, et al. Lack of interaction between famotidine and warfarin. Int J Clin Pharmacol Res. 1990;10:167-171.
115. Grind M, Murphy M, Warrington S, Aberg J. Method for studying drug-warfarin interactions. Clin Pharmacol Ther. 1993;54:381-387.
116. Rowe H, Carmichael R, Lemberger L. The effect of fluoxetine on warfarin metabolism in the rat and man. Life Sci. 1978;23:807-812.
117. Toon S, Holt BL, Mullins FG, Bullingham R, Aarons L, Rowland M. Investigations into the potential effects of multiple dose ketorolac on the pharmacokinetics and pharmacodynamics of racemic warfarin. Br J Clin Pharmacol. 1990;30:743-750.
118. Benedek IH, King SY, Powell RJ, Agra AM, Schary WL, Pieniaszek HJ Jr. Effect of moricizine on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. J Clin Pharmacol. 1992;32:558-563.
119. Jain A, McMahon FG, Slattery JT, Levy G. Effect of naproxen on the steady-state serum concentration and anticoagulant activity of warfarin. Clin Pharmacol Ther. 1979;25:61-66.
120. Cournot A, Berlin I, Sallord JC, Singlas E. Lack of interaction between nizatidine and warfarin during chronic administration. J Clin Pharmacol. 1988;28:1120-1122.
121. Serlin MJ, Sibeon RG, Breckenridge AM. Lack of effect of ranitidine on warfarin action. Br J Clin Pharmacol. 1981;12:791-794.
122. Orme M, Breckenridge A, Cook P. Warfarin and distalgesic interaction. BMJ. 1976;1:200.
123. Davydov L, Yermolnik M, Cuni LJ. Warfarin and amoxicillin/clavulanate drug interaction. Ann Pharmacother. 2003;37:367-370.
124. Foster DR, Milan NL. Potential interaction between azithromycin and warfarin. Pharmacotherapy. 1999;19:902-908.
125. Udall JA. Warfarin interactions with chloral hydrate and glutethimide. Curr Ther Res Clin Exp. 1975;17:67-74.
126. Byers M. Clarithromycin-warfarin interaction resulting in an elevated INR. Can J Hosp Pharm. 1997;50:285-287.
127. Izzat MB, Yim AP, El Zufari MH. A taste of Chinese medicine. Ann Thorac Surg. 1998;66:941-942.
128. Smith R, Prudden D, Hawkes C. Propoxyphene and warfarin interaction [letter]. Drug Intell Clin Pharm. 1984;18:822.
129. O'Reilly RA. Dynamic interaction between disulfiram and separated enantiomorphs of racemic warfarin. Clin Pharmacol Ther. 1981;29:332-336.
130. Page RL, Lawrence JD. Potentiation of warfarin by dong quai. Pharmacotherapy. 1999;19:870-876.
131. Carabino J, Wang F. International normalized ratio fluctuation with warfarin-fluorouracil therapy [letter]. Am J Health Syst Pharm. 2002;59:875.
132. Trilli LE, Kelley CL, Aspinall SL, Kroner BA. Potential interaction between warfarin and fluvastatin. Ann Pharmacother. 1996;30:1399-1402.
133. Limke KK, Shelton AR, Elliott ES. Fluvoxamine interaction with warfarin. Ann Pharmacother. 2002;36:1890-1892.
134. Kinikar SA, Kolesar JM. Identification of a gemcitabine-warfarin interaction. Pharmacotherapy. 1999;19:1331-1333.
135. Bartle WR. Grapefruit juice might still be factor in warfarin response [letter]. Am J Health Syst Pharm. 1999;56:676.
136. Adachi Y, Yokoyama Y, Nanno T, Yamamoto T. Potentiation of warfarin by interferon. BMJ. 1995;311:292.
137. Yeh J, Soo SC, Summerton C, Richardson C. Potentiation of action of warfarin by itraconazole. BMJ. 1990;301:669.
138. Scarfe MA, Israel MK. Possible drug interaction between warfarin and combination of levamisole and fluorouracil. Ann Pharmacother. 1994;28:464-467.
139. Ravnan SL, Locke C. Levofloxacin and warfarin interaction. Pharmacotherapy. 2001;21:884-885.
140. Lam AY, Elmer GW, Mohutsky MA. Possible interaction between warfarin and Lycium barbarum L. Ann Pharmacother. 2001;35:1199-1201.
141. Davis NB, Nahlik L, Vogelzang NJ. Does PC-SPES interact with warfarin? J Urol. 2002;167:1793.
142. Thompson ME, Highley MS. Interaction between paclitaxel and warfarin [letter]. Ann Oncol. 2003;14:500.
143. Fitzmaurice DA, Murray JA. Potentiation of the anticoagulant effect of warfarin. Postgrad Med J. 1997;73:439-440.
144. Levine M, Sheppard I. Biphasic interaction of phenytoin with warfarin. Clin Pharm. 1984;3:200-203.
145. Koch-Weser J. Quinidine-induced hypoprothrombinemic hemorrhage in patients on chronic warfarin therapy. Ann Intern Med. 1968;68:511-517.
146. Bair JD, Oppelt TF. Warfarin and ropinirole interaction. Ann Pharmacother. 2001;35:1202-1204.
147. Gaw A, Wosornu D. Simvastatin during warfarin therapy in hyperlipoproteinaemia [letter]. Lancet. 1992;340:979-980.
148. Lin JC, Ito MK, Stolley SN, Morreale AP, Marcus DB. The effect of converting from pravastatin to simvastatin on the pharmacodynamics of warfarin. J Clin Pharmacol. 1999;39:86-90.
149. Lodwick R, McConkey B, Brown AM. Life threatening interaction between tamoxifen and warfarin. Br Med J (Clin Res Ed). 1987;295:1141.
150. Westfall LK. An unrecognized cause of warfarin resistance [letter]. Drug Intell Clin Pharm. 1981;15:131.
151. Danos EA. Apparent potentiation of warfarin activity by tetracycline. Clin Pharm. 1992;11:806-808.
152. Colucci VJ, Rivey MP. Tolterodine-warfarin drug interaction. Ann Pharmacother. 1999;33:1173-1176.
153. Sabbe JR, Sims PJ, Sims MH. Tramadol-warfarin interaction. Pharmacotherapy. 1998;18:871-873.
154. Scher ML, Huntington NH, Vitillo JA. Potential interaction between tramadol and warfarin [letter]. Ann Pharmacother. 1997;31:646-647.
155. Plowman BK, Morreale AP. Possible troglitazone-warfarin interaction [letter]. Am J Health Syst Pharm. 1998;55:1071.
156. Rotenberg M, Levy Y, Shoenfeld Y, Almog S, Ezra D. Effect of azathioprine on the anticoagulant activity of warfarin. Ann Pharmacother. 2000;34:120-122.
157. Murphey LM, Hood EH. Bosentan and warfarin interaction. Ann Pharmacother. 2003;37:1028-1031.
158. Jonkman JH, van Lier JJ, van Heiningen PN, Lins R, Sennewald R, Hogemann A. Pharmacokinetic drug interaction studies with candesartan cilexetil. J Hum Hypertens. 1997;11(suppl 2):S31-S35.
159. Grebe HB, Gregory PJ. Inhibition of warfarin anticoagulation associated with chelation therapy. Pharmacotherapy. 2002;22:1067-1069.
160. Krstenansky PM, Jones WN, Garewal HS. Effect of dicloxacillin sodium on the hypoprothrombinemic response to warfarin sodium. Clin Pharm. 1987;6:804-806.
161. Mailloux AT, Gidal BE, Sorkness CA. Potential interaction between warfarin and dicloxacillin. Ann Pharmacother. 1996;30:1402-1407.
162. Rosado MF. Thrombosis of a prosthetic aortic valve disclosing a hazardous interaction between warfarin and a commercial ginseng product. Cardiology. 2003;99:111.
163. Kurnik D, Lubetsky A, Loebstein R, Almog S, Halkin H. Multivitamin supplements may affect warfarin anticoagulation in susceptible patients. Ann Pharmacother. 2003;37:1603-1606.
164. Miller JW, Skerjanec A, Knadler MP, Ghosh A, Allerheiligen SRB. Divergent effects of raloxifene HCl on the pharmacokinetics and pharmacodynamics of warfarin. Pharm Res. 2001;18:1024-1028.
165. Knoell KR, Young TM, Cousins ES. Potential interaction involving warfarin and ritonavir. Ann Pharmacother. 1998;32:1299-1302.
166. Cambria-Kiely JA. Effect of soy milk on warfarin efficacy. Ann Pharmacother. 2002;36:1893-1896.
167. Stern R, Abel R, Gibson GL, Besserer J. Atorvastatin does not alter the anticoagulant activity of warfarin. J Clin Pharmacol. 1997;37:1062-1064.
168. Kelly J, Murdoch RD, Clark DJ, Webber DM, Fuder H. Warfarin pharmacodynamics unaffected by cilomilast. Ann Pharmacother. 2001;35:1535-1539.
169. Donovan JM, Stypinski D, Stiles MR, Olson TA, Burke SK. Drug interactions with colesevelam hydrochloride: a novel potent lipid-lowering agent. Cardiovasc Drugs Ther. 2000;14:681-690.
170. Schulman S, Henriksson K. Interaction of ibuprofen and warfarin on primary haemostasis. Br J Rheumatol. 1989;28:46-49.
171. Brass C, Galgiani JN, Blaschke TF, Defelice R, O'Reilly RA, Stevens DA. Disposition of ketoconazole an oral antifungal in humans. Antimicrob Agents Chemother. 1982;21:151-158.
172. Mieszczak C, Winther K. Lack of interaction of ketoprofen with warfarin. Eur J Clin Pharmacol. 1993;44:205-206.
173. Antila S, Jarvinen A, Honkanen T, Lehtonen L. Pharmacokinetic and pharmacodynamic interactions between the novel calcium sensitiser levosimendan and warfarin. Eur J Clin Pharmacol. 2000;56:705-710.
174. Morreale AP, Janetzky K. Probable interaction of warfarin and acarbose. Am J Health Syst Pharm. 1997;54:1551-1552.
175. Woeber KA, Warner I. Potentiation of warfarin sodium by amiodarone-induced thyrotoxicosis. West J Med. 1999;170:49-51.
176. Bandrowsky T, Vorono AA, Borris TJ, Marcantoni HW. Amoxicillin-related postextraction bleeding in an anticoagulated patient with tranexamic acid rinses. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996;82:610-612.
177. Malacarne P, Maestri A. Possible interactions between antiblastic agents and warfarin inducing prothrombin time abnormalities [letter]. Recenti Prog Med. 1996;87:135.
178. Leone R, Ghiotto E, Conforti A, Velo G. Potential interaction between warfarin and ocular chloramphenicol [letter]. Ann Pharmacother. 1999;33:114.
179. Suvarna R, Pirmohamed M, Henderson L. Possible interaction between warfarin and cranberry juice. BMJ. 2003;327:1454.
180. Yue Q, Jansson K. Herbal drug curbicin and anticoagulant effect with and without warfarin: possibly related to the vitamin E component [letter]. J Am Geriatr Soc. 2001;49:838.
181. Booth CD. Drug interaction between danazol and warfarin. Pharm J. 1993;250:439-440.
182. Tam LS, Chan TY, Leung WK, Critchley JA. Warfarin interactions with Chinese traditional medicines: danshen and methyl salicylate medicated oil [letter]. Aust N Z J Med. 1995;25:258.
183. Sylven C, Anderson P. Evidence that disopyramide does not interact with warfarin. Br Med J (Clin Res Ed). 1983;286:1181.
184. Haworth E, Burroughs AK. Disopyramide and warfarin interaction. BMJ. 1977;2:866-867.
185. Tisdel KA, Israel DS, Kolb KW. Warfarin-felbamate interaction: first report [letter]. Ann Pharmacother. 1994;28:805.
186. Artymowicz RJ, Cino BJ, Rossi JG, Walker JL, Moore S. Possible interaction between gatifloxacin and warfarin. Am J Health Syst Pharm. 2002;59:1205-1206.
187. Rindone JP, Keng HC. Gemfibrozil-warfarin drug interaction resulting in profound hypoprothrombinemia. Chest. 1998;114:641-642.
188. Chan TY, Lui SF, Chung SY, Luk S, Critchley JA. Adverse interaction between warfarin and indomethacin. Drug Saf. 1994;10:267-269.
189. Hall G, Lind MJ, Huang M, et al. Intravenous infusions of ifosfamide/mesna and perturbation of warfarin anticoagulant control. Postgrad Med J. 1990;66:860-861.
190. Ahmad S. Lovastatin: warfarin interaction. Arch Intern Med. 1990;150:2407.
191. Lim V, Pande I. Leflunomide can potentiate the anticoagulant effect of warfarin. BMJ. 2002;325:1333.
192. Trewin VF. A probable interaction between warfarin and metolazone. Pharm J. 1988;18:781-782.
193. Evans J, Orme DS, Sedgwick ML, Youngs GR. Treating oral candidiasis: potentially fatal [letter]. Br Dent J. 1997;182:452.
194. Leor J, Levartowsky D, Sharon C. Interaction between nalidixic acid and warfarin [letter]. Ann Intern Med. 1987;107:601.
195. Linville T, Matanin D. Norfloxacin and warfarin. Ann Intern Med. 1989;110:751-752.
196. Leor J, Matetzki S. Ofloxacin and warfarin [letter]. Ann Intern Med. 1988;109:761.
197. Baciewicz AM, Ashar BH, Locke TW. Interaction of ofloxacin and warfarin [letter]. Ann Intern Med. 1993;119:1223.
198. MacWalter RS, Fraser HW, Armstrong KM. Orlistat enhances warfarin effect. Ann Pharmacother. 2003;37:510-512.
199. Littleton F. Warfarin and topical salicylates [letter]. JAMA. 1990;263:2888.
200. Chow WH, Cheung KL, Ling HM, See T. Potentiation of warfarin anticoagulation by topical methylsalicylate ointment. J R Soc Med. 1989;82:501-502.
201. Darlington MR. Hypoprothrombinemia during concomitant therapy with warfarin and saquinavir [letter]. Ann Pharmacother. 1997;31:647.
202. Carter SA. Potential effect of sulindac on response of prothrombin-time to oral anticoagulants. Lancet. 1979;2:698-699.
203. Ross JR, Beeley L. Sulindac prothrombin time and anticoagulants [letter]. Lancet. 1979;2:1075.
204. Gidal BE, Sorkness CA, McGill KA, Larson R, Levine RR. Evaluation of a potential enantioseleotive interaction between ticlopidine and warfarin in chronically anticoagulated patients. Ther Drug Monit. 1995;17:33-38.
205. Koren JF, Cochran DL, Janes RL. Tolmetin-warfarin interaction. Am J Med. 1987;82:1278-1280.
206. Nissenblatt MJ, Karp GI. Bleeding risk with trastuzumab (Herceptin) treatment. JAMA. 1999;282:2299-2301.
207. Snyder DS. Interaction between cyclosporine and warfarin [letter]. Ann Intern Med. 1988;108:311.
208. Ostlere LS, Langtry JA, Jones S, Staughton RC. Reduced therapeutic effect of warfarin caused by etretinate [letter]. Br J Dermatol. 1991;124:505.
209. Teefy AM, Martin JE, Kovacs MJ. Warfarin resistance due to sulfasalazine. Ann Pharmacother. 2000;34:1265-1268.
210. Bartle WR, Madorin P, Guylaine F. Seaweed, vitamin K, and warfarin [letter]. Am J Health Syst Pharm. 2001;58:2300.
211. Stangier J, Su CA, Hendriks MG, et al. Steady-state pharmacodynamics and pharmacokinetics of warfarin in the presence and absence of telmisartan in healthy male volunteers. J Clin Pharmacol. 2000;40:1331-1337.
212. Spigset O. Reduced effect of warfarin caused by ubidecarenone [letter]. Lancet. 1994;344:1372-1373.
213. Beringer TR. Warfarin potentiation with bezafibrate. Postgrad Med J. 1997;73:657-658.
214. Angaran DM, Dias VC, Arom KV, et al. The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient: cefamandole cefazolin vancomycin. Ann Surg. 1987;206:155-161.
215. Le AT, Hasson NK, Lum BL. Enhancement of warfarin response in a patient receiving etoposide and carboplatin chemotherapy. Ann Pharmacother. 1997;31:1006-1008.
216. Thomas P, Fennerty A, Blackhouse G. Oral anticoagulant during treatment with heparin. Br Med J (Clin Res Ed). 1984;288:191.
217. Wehbe TW, Warth JA. A case of bleeding requiring hospitalization that was likely caused by an interaction between warfarin and levamisole. Clin Pharmacol Ther. 1996;59:360-362.
218. Ellison J. Apparent interaction between warfarin and levonorgestrel used for emergency contraception. BMJ. 2000;321:1382.
219. Kaufman M. Treatment of multiple sclerosis with high-dose corticosteroids may prolong the prothrombin time to dangerous levels in patients taking warfarin. Mult Scler. 1997;3:248-249.
220. Dennis VC, Thomas BK, Hanlon JE. Potentiation of oral anticoagulation and hemarthrosis associated with nabumetone. Pharmacotherapy. 2000;20:234-239.
221. Rogers T, de Leon J, Atcher D. Possible interaction between warfarin and quetiapine [letter]. J Clin Psychopharmacol. 1999;19:382-383.
222. Sioris LJ, Weibert RT, Pentel PR. Potentiation of warfarin anticoagulation by sulfisoxazole. Arch Intern Med. 1980;140:546-547.
223. Ibrahim OM, Allam A. Warfarin resistance in a patient with prosthetic valve endocarditis treated with cloxacillin. Saudi Pharm J. 1996;4:56-59.
224. Laizure SC, Madlock L, Cyr M, Self T. Decreased hypoprothrombinemic effect of warfarin associated with furosemide. Ther Drug Monit. 1997;19:361-363.
225. Taylor JR, Wilt VM. Probable antagonism of warfarin by green tea. Ann Pharmacother. 1999;33:426-428.
226. Setter SM, Lawless K, Hunter KA. Need for continuity of care in patients receiving warfarin and nafcillin/dicloxacillin. Hosp Pharm. 1996;31:1269-1271.
227. MacLaren R, Wachsman BA, Swift DK, Kuhl DA. Warfarin resistance associated with intravenous lipid administration: discussion of propofol and review of the literature. Pharmacotherapy. 1997;17:1331-1337.
228. Agosta FG, Liberato NL, Chiofalo F. Warfarin resistance induced by teicoplanin [letter]. Haematologica. 1997;82:637-638.
229. May JR, DiPiro JT, Sisley JF. Drug interactions in surgical patients. Am J Surg. 1987;153:327-335.
230. Gabb GM. Fatal outcome of interaction between warfarin and a non-steroidal anti-inflammatory drug [letter]. Med J Aust. 1996;164:700-701.
231. Baciewicz AM, Menke JJ, Bokar JA, Baud EB. Fluconazole-warfarin interaction [letter]. Ann Pharmacother. 1994;28:1111.
232. Haase KK, Rojas-Fernandez CH, Lane L, Frank DA. Potential interaction between celecoxib and warfarin. Ann Pharmacother. 2000;34:666-667.
233. Janetzky K, Morreale AP. Probable interaction between warfarin and ginseng. Am J Health Syst Pharm. 1997;54:692-693.
234. Holbrook AM, Wells PS, Crowther NR. Pharmacokinetics and drug interactions with warfarin. In: Poller L, Hirsh J, eds. Oral Anticoagulants. Dunton Green, England: Hodder and Stoughton; 1996.
235. Indiana University Department of Medicine Web site. Cytochrome P450 drug interaction table. Available at: http://medicine.iupui.edu/flockhart/table.htm. Accessed July 15, 2004.
236. O'Reilly RA. Stereoselective interaction of trimethoprim-sulfamethoxazole with the separated enantiomorphs of racemic warfarin in man. N Engl J Med. 1980;302:33-35.
237. Hirsh J, Ansell J, Ansell J, Halperin JL. American Heart Association/American College of Cardiology foundation guide to warfarin therapy. Circulation. 2003;107:1692-1711.
238. Harris JE. Interaction of dietary factors with oral anticoagulants: review and applications. J Am Diet Assoc. 1995;95:580-584.
239. O'Reilly RA, Rytand D. "Resistance" to warfarin due to unrecognized vitamin K supplementation [letter]. N Engl J Med. 1980;303:160-161.
240. Pedersen FM, Hamburg O, Hess K, Ovesen L. The effect of dietary vitamin K on warfarin-induced anticoagulants. J Intern Med. 1991;229:517-520.
241. Owens JC, Neely JB, Owen WR. Effect of sodium dextrothyroxine in patients receiving anticoagulation. N Engl J Med. 1962;266:76-79.
242. Antlitz AM, Mead JA Jr, Tolentino MA. Potentiation of oral anticoagulant therapy by acetaminophen. Curr Ther Res Clin Exp. 1968;10:501-507.
243. Hylek EM, Heiman H, Skates SJ, Sheehan MA, Singer DE. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA. 1998;279:657-662.
244. Kwan D, Bartle WR, Walker SE. The effects of acetaminophen on pharmacokinetics and pharmacodynamics of warfarin. J Clin Pharmacol. 1999;39:68-75.
245. Gianni LM, Dreitlein WB. Some popular OTC herbals can interact with anticoagulant therapy. US Pharm. 1998;23:80, 83-84, 86.
246. Joshi BS, Kaul PN. Alternative medicine: herbal drugs and their critical appraisal - part I. Prog Drug Res. 2001;56:1-76.
247. Holbrook AM, Janjusevic V, Keshavjee K, Lee HK. Measuring quality of prescribing: where does the information reside? [abstract]. Can J Clin Pharmacol. 2002;9:40.
248. Holbrook AM, Keshavjee K, Goldsmith CH, Tucker J, Park L. Advancing the measurement of quality of care using electronic medical records. Proc Towards Electron Patient Rec. 1999;1:848-855.